It is unknown whether maintaining lower SF levels in persons with HFE hemochromatosis and diabetes than presently recommended for “maintenance” therapy could maintain or improve insulin secretion and diabetes control or decrease diabetes risk. This evidence concerns the gene INS and hemochromatosis type 1.